CD274 and type 1 diabetes mellitus: Pharmacologically blocking the PD-1/PD-L1 pathway is theorized to act on two fronts: islet T lymphocytes release more interferon and activate monocytes that target β-cells, and, in already susceptible patients, due to the alterations detailed in the previous phrase, ICI treatment may be the definitive trigger that kickstarts the type 1 diabetes [21,22].